Skip to content
Welcome
  • Welcome to NJ Vaccine Science
  • Recent Blog Post
  • About NJ Vaccine Science

NJ Vaccine Science

A site dedicated to making the case for vaccine exemptions using CDC statements, vaccine inserts, and peer reviewed science.

  • Vaccine Safety
    • Adverse Events After Vaccination – How Often They Occur
    • Adverse Effects of Vaccines Evidence and Causality – 2012 IOM Report
    • Immunity for Vaccine Manufactures & HHS Failure to Submit Safety Reports
    • Plotkin Deposition
    • WHO Global Vaccine Safety Summit
    • ACIP Meeting for Hepislav-B
    • DTP: The Story of an Unsafe Vaccine
  • Cost-Benefit Analysis
    • Hep B
    • Pertussis
    • Influenza
    • NJ Assembly Woman Vandervalk – Protecting an at-risk population
  • Herd Immunity
    • Problems with Herd Immunity: District 11 Stories
      • The Medically Complicated: Keanu
      • Vaccine Injury: Gio
      • The Medically Complicated: Michael
    • Measles & Herd Immunity
  • COVID
    • The Overwhelming Evidence for Keeping Schools Open
    • How to tell the magnitude of NJ’s second wave?
    • FLU SHOT MANDATE: WILL IT HELP DURING COVID-19?
    • Alan Dershowitz and Paul Offit Advocate for Vaccine Choice
    • CDC, Oxford, Stanford Agree, COVID-19 IFR is under 0.3%
COVID

Pfizer/BioN Tech COVID-19 Vaccine Concerns

- December 16, 2020 - NJ Vaccine Science

1. Vaccine Safety:

A. No Long-Term Data:We do not have safety data for this vaccine beyond the two months of phase 3 data that has been released. There is a legitimate concern that if too many people cross over from the placebo group to the vaccine group, there will never be enough data to establish long term safety and efficacy data.

B. No Data from Important Groups:According to Pfizer’s FDA Briefing Document: “There are currently insufficient data to make conclusions about the safety of the vaccine in subpopulations such as children less than 16 years of age, pregnant and lactating individuals, and immunocompromised individuals.”

C. Limited Data from COVID’s Most Vulnerable: Only 4.3% of the trial 3 population was over 75 years old and there were zero participant over 80 years old. One CDC scientist, Dr. Helen Talbot of Vanderbilt University, voted against allowing long-term care residents to receive the emergency vaccinations explaining, “I have spent my career studying vaccines in older adults. And we have traditionally tried a vaccine in a young healthy population and then hoped it works in our frail older adults, and so we enter this realm of ‘we hope it works, and we hope it’s safe,’ and that concerns me on many levels.”

D. Allergic Reactions: Two British and an Alaskan health care worker with no history of allergies had an “anaphylactoid reaction, which tends to involve a skin rash, breathlessness and sometimes a drop in blood pressure. This is not the same as anaphylaxis which can be fatal.” Sarah Mbaeyi, a medical officer with the CDC recently stated “People that do report those types of anaphylactic reactions to other vaccines or injectables — they can still get the vaccine, but they should be counseled about the unknown risks of developing a severe allergic reaction and balance these risks against the benefit of vaccination.” According to the Stat News, “Severe allergic reactions to vaccines are extremely rare and were also rare during the Pfizer/BioNTech trial, which excluded people with a history of anaphylaxis.”

E. Bells Palsy: According to Pfizer’s FDA Briefing Document: “Among non-serious unsolicited adverse events, there was a numerical imbalance of four cases of Bell’s palsy in the vaccine group compared with no cases in the placebo group, though the four cases in the vaccine group do not represent a frequency above that expected in the general population.”

2. Post Vaccination Transmission:
According to Pfizer’s FDA Briefing Document : “Data are limited to assess the effect of the vaccine against transmission of SARS-CoV-2 from individuals who are infected despite vaccination. Additional evaluations including data from clinical trials and from vaccine use post-authorization will be needed to assess the effect of the vaccine in preventing virus shedding and transmission, in particular in individuals with asymptomatic infection.”

The design of the phase 3 clinical trials is not to determine if the vaccine can prevent transmission or severe COVID and death (see below) as Peter Doshi, associate editor of the British Medical Journal pointed out here and here .

Additionally, according to the briefing document : “Data are limited to assess the effect of the vaccine against asymptomatic infection as measured by detection of the virus and/or detection of antibodies against non-vaccine antigens that would indicate infection rather than an immune response induced by the vaccine. Additional evaluations will be needed to assess the effect of the vaccine in preventing asymptomatic infection, including data from clinical trials and from the vaccine’s use post-authorization.”

3. Severe COVID & Death:

According to Pfizer’s FDA Briefing Document : “COVID-19 disease may have long-term effects on certain organs, and at present it is not possible to assess whether the vaccine will have an impact on specific long-term sequelae of COVID-19 disease in individuals who are infected despite vaccination.“

“Additional evaluations will be needed to assess the effect of the vaccine in preventing long-term effects of COVID-19, including data from clinical trials and from the vaccine’s use postauthorization.”

“A larger number of individuals at high risk of COVID-19 and higher attack rates would be needed to confirm efficacy of the vaccine against mortality.”

Post navigation

The Overwhelming Evidence for Keeping Schools Open
The Case for Unmasking NJ’s Children

Take Action:

1. Sign up for NJ Vaccine Science action alerts via email.

2. Stay Informed – check our our Blog and Advocacy Home page for action items, follow us on Twitter, and like us on Facebook.

3. Call and Email your Senator and Assemblymembers – ask them to oppose bill S902/A969. Use this link to find your representatives’ phone number and send them a message.

4. Call and Email the Bill Sponsors: Senate President Sweeney: [email protected] / 856-251-9801; Assemblyman Conway  [email protected] / (856) 461-3997

If you live in Legislative District 11 sign our D11 Petition to protect NJ’s RE. 

Contact NJ Vaccine Science at:

[email protected]

Sign Up for Email Action Alerts

Email Address *

First Name *

Last Name *

* indicates required


Other Useful Websites:

Hope from Holly

Vaccine Papers

National Vaccine Information Center

Informed Consent Action Network

Vaccine Injury and Compensation Program

DISCLAIMER:

All information, data and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advise. The decision to vaccinate and how you implement that decision is yours and yours alone. You are encouraged to consult with your medical professional and legal adviser.

powered by XBlog Plus WordPress Theme